

Condylox® (podofilox) - First-time generic

- On December 7, 2023, <u>Padagis launched</u> an <u>AB-rated</u> generic version of AbbVie's <u>Condylox</u> (podofilox) gel.
 - Padagis was granted Competitive Generic Therapy exclusivity providing a 180 day market exclusivity period.
- Condylox is approved for the topical treatment of anogenital warts (external genital warts and perianal warts).
- Podofilox is also available generically as a <u>topical solution</u> approved for the treatment of external genital warts.
- According to IQVIA Health, Condylox gel had annual sales of \$9 million as of December 2022.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.